Global Research Trends in Metabolic Syndrome, Medical Imaging, and Medical Radiation Science

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 6241

Special Issue Editors


E-Mail Website
Guest Editor
Health and Social Sciences Cluster, Singapore Institute of Technology, SIT@Dover, 10 Dover Drive, Singapore 138683, Singapore
Interests: metabolic syndromes; ultrasonography and MRI in vascular, musculoskeletal and nervous systems; endothelial dysfunction and atherosclerosis in diabetes; radiography education development; computed tomography; artificial intelligence
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Center of Radiation Research and Medical Imaging, Chiang Mai University, Chiang Mai, Thailand
2. Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
Interests: magnetic resonance imaging; in vivo and in vitro nuclear magnetic resonance spectroscopy; paramagnetic nanoparticles; contrast agents; polyphenol and antioxidant; multidrug resistance; radiobiology; radiation shielding material; dosimetry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolic syndrome (MetS) is a group of symptoms that raise the risk of heart disease, stroke, and type 2 diabetes. MetS has become a major concern for the public healthcare system in many countries, resulting in a huge fiscal and societal burden. Therefore, the primary aims of this Special Issue are to address the threats of metabolic syndrome (or any one of the classical risk markers of MetS) to an individual and the healthcare system, as well as to understand the global research trends on early detection and emerging surrogate and biomarkers, particularly the use of medical imaging. Medical imaging is crucial for all levels of health care and enables early detection. 

This Special Issue also welcomes other related topics such as aging, oxidative stress, and basic science. In addition, original research articles, brief reports, review papers, and other concepts related to metabolic syndrome, medical imaging, and medical radiation science will be considered.

Dr. Christopher Lai
Dr. Suchart Kothan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic syndrome
  • medical imaging
  • Medical Radiation Sciences

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 712 KiB  
Article
Prevalence Trends of Metabolic Syndrome among Korean Children and Adolescents from a Population-Based Cross-Sectional Survey
by Ji Hyun Kim and Jung Sub Lim
Life 2022, 12(9), 1404; https://doi.org/10.3390/life12091404 - 9 Sep 2022
Cited by 6 | Viewed by 1618
Abstract
The prevalence of metabolic syndrome (MetS) is increasing worldwide. This study aimed to investigate the prevalence trend of metabolic syndrome among Korean adolescents and to examine the effect of changes in dietary components on metabolic syndrome components. It has used the data of [...] Read more.
The prevalence of metabolic syndrome (MetS) is increasing worldwide. This study aimed to investigate the prevalence trend of metabolic syndrome among Korean adolescents and to examine the effect of changes in dietary components on metabolic syndrome components. It has used the data of children and adolescents (8718 subjects aged 10–18) from the National Health and Nutrition Survey IV-VII (KNHANES 2007–2018) to estimate the recent prevalence of MetS and identify related nutritional factors. The definition of MetS used modified NCEP-ATP III and IDF criteria. The prevalence of MetS among Korean adolescents in 2007–2018 was 4.6% using the modified NCEP-ATP III criteria, and the trend of MetS increased significantly (p trend = 0.02). In the overweight and obese groups, the risk of MetS increased 7.08 (95% CI, 5.19–9.79) and 27.13 (95% CI, 20.90–35.24) compared to the normal-weight group. During KNHANES IV-VII, overall caloric intake increased, carbohydrate and sodium intake decreased, but fat intake increased (KNHANE-IV; 21.3% to VII; 24.0%, p < 0.001). These fat intakes were significantly correlated with an increase in systolic blood pressure, fasting blood glucose, and waist circumference. The prevalence of MetS is also increasing in Korean adolescents, and changes in dietary habits are related. In the future, it is also necessary to study the relationship of MetS to lifestyle. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

12 pages, 942 KiB  
Review
A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review
by Ipek Cicekli, Duygu Saglam and Nadir Takar
Life 2023, 13(7), 1608; https://doi.org/10.3390/life13071608 - 22 Jul 2023
Cited by 3 | Viewed by 1524
Abstract
Metabolic syndrome (MetS) imposes a substantial burden on the healthcare systems and economies of countries and is a major public health concern worldwide. MetS is mainly caused by an imbalance between calorie intake and energy expenditure; however, it is recognized that additional variables, [...] Read more.
Metabolic syndrome (MetS) imposes a substantial burden on the healthcare systems and economies of countries and is a major public health concern worldwide. MetS is mainly caused by an imbalance between calorie intake and energy expenditure; however, it is recognized that additional variables, such as chronic inflammation, may have the same predictive potential as insulin resistance or MetS components in the genesis of type 2 diabetes and cardiovascular events. More importantly, the early diagnosis or treatment of MetS may significantly reduce the burden on the health systems of the disease with any prevention or biomarker and should not be underestimated. Osteopontin (OPN), also called secreted phosphoprotein 1, is a soluble protein found mostly in body fluids. Studies suggest that serum OPN levels may be an early and new biomarker to predict metabolic and cardiovascular complications significantly associated with some diseases. This review aims to provide specific insight into the new biomarker OPN in MetS. With this purpose, it is examined the link between the MetS cornerstones and OPN. In addition, the interaction between the microbiota and MetS is predicted to be bidirectional, and the microbiota may act as a bridge in this interaction process. Increased OPN levels may have unfavourable consequences for cardiovascular diseases, diabetes, and obesity, all of which are components of MetS. Further studies are required to evaluate the use of OPN levels as a clinical biomarker risk of MetS. Full article
Show Figures

Figure 1

10 pages, 632 KiB  
Review
Metabolic Comorbidities in Pediatric Atopic Dermatitis: A Narrative Review
by Edoardo De Simoni, Giulio Rizzetto, Elisa Molinelli, Guendalina Lucarini, Monica Mattioli-Belmonte, Irene Capodaglio, Gianna Ferretti, Tiziana Bacchetti, Annamaria Offidani and Oriana Simonetti
Life 2023, 13(1), 2; https://doi.org/10.3390/life13010002 - 20 Dec 2022
Cited by 6 | Viewed by 2198
Abstract
Atopic dermatitis (AD) is an itchy dermatitis with multifactorial aetiology, chronic-recurrent course, and typical distribution of lesions according to the age, affecting the 10–20% of pediatric population. Patients with AD, including children, suffer from many metabolic comorbidities, including metabolic syndrome, being overweight, obesity, [...] Read more.
Atopic dermatitis (AD) is an itchy dermatitis with multifactorial aetiology, chronic-recurrent course, and typical distribution of lesions according to the age, affecting the 10–20% of pediatric population. Patients with AD, including children, suffer from many metabolic comorbidities, including metabolic syndrome, being overweight, obesity, dyslipidaemia, and arterial hypertension, all of which had a prevalence that was demonstrated to be higher than in healthy patients. The association between AD and metabolic comorbidities is multifactorial and involves the deregulation of immune system. In fact, hypertrophic adipose tissue produces soluble adipokines involved in inflammation and immunity, which stimulate the production of pro-inflammatory cytokines, responsible for a chronic low-grade inflammatory state and a higher predisposition to hypersensitivity reactions. Especially in pediatric population with AD, these metabolic disorders are usually underestimated and are associated with long term sequelae and an increased risk of a cardiovascular event, which may also occur later in adult age. Therefore, metabolic comorbidities should be carefully evaluated and early treated in children with AD, to minimize the long-term risk of cardiovascular events. Full article
Show Figures

Figure 1

Back to TopTop